Comparing and using the scenarios

1
Comparing and using the scenarios
2
Example ODA
3
Example Exploring issues
Intellectual Property
extension of TRIPS compliance period by 10 years
(to 2026).. pragmatic solutions mix of generic
import, local manufacture, deep
discounts.. Generic production of older ARVs is
normal practice debate on making newer patented
drugs more quickly available
Tough Choices
deeply polarised positions on global IP no
agreement to extend TRIPS Technology transfer
takes backseat to security concerns drug quality
control, distribution and counterfeiting problems
Traps and Legacies
Times of Transition
transformation of TRIPS traditional and genetic
IP flexibility of poorer countries to decide
when/how to use patent protection open source
models of drug development, including neglected
diseases regulation of the supply of medicines
4
Infections averted
5
Cumulative Expenditure
6
Annual new adult infection rates